1. Scrip
  2. >>Business
  3. >>Deals

Pharma On The Hunt For Oncology Partners Across Modalities

For Novel Targets, New Approaches To Known Targets

 
• By Mandy Jackson

The Inaugural AACR Oncology Industry Partnering Event gave pharma firms an opportunity to tell potential cancer drug collaborators what they need from external sources.

Tumor microenvironment concept with cancer cells, T-Cells, nanoparticles, cancer associated fibroblast layer of tumor microenvironment
Pharma firms expressed interest in new drug candidates, platforms and other technologies • Source: Shutterstock

Figuring out how to get a foot in the door with potential big pharma partners is a daunting task for academic researchers and small biotechnology companies. The organizers of the inaugural American Association of Cancer Research (AACR) Oncology Industry Partnering Event hope the two-day meeting will help academics and biotech executives take their first steps toward pharma firms hungry for the next big ideas in cancer drug development.

Key Takeaways

  • Big pharma companies gave potential academic and biotech collaborators a look at their cancer R&D and dealmaking strategies during the inaugural AACR Oncology Industry Partnering Event.

  • Organizers assembled the first-time event to help researchers and small company executives struggling to make connections with pharma business development groups

Twelve big pharma companies descended on San Diego for the partnering event on 4-5 April, just ahead of AACR’s annual meeting that wrapped up on 10 April, to outline their cancer drug research and development strategies, including their business development priorities

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

More from Business